Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1889501 | 0.91 | CPT1A (0.37) | F11 | |
| SCHEMBL12661219 | 0.90 | GPR119 (0.36) | TSHRLMNAMEN1MAPTKMT2A | |
| SCHEMBL12661150 | 0.90 | ALDH1A1 (0.37) | TSHRLMNAMEN1MAPTKMT2A | |
| SCHEMBL1887118 | 0.90 | CHEK2 (0.38) | TSHRLMNAMEN1MAPTKMT2A | |
| SCHEMBL1888626 | 0.89 | DGAT1 (0.37) | TSHRLMNAMEN1MAPTKMT2A | |
| SCHEMBL12661239 | 0.89 | ALDH1A1 (0.36) | TSHRLMNAMEN1MAPTKMT2A | |
| SCHEMBL9281762 | 0.88 | ALDH1A1 (0.41) | TSHRLMNAMEN1MAPTKMT2A | |
| SCHEMBL1884887 | 0.88 | ALDH1A1 (0.36) | TSHRLMNAMEN1MAPTKMT2A | |
| SCHEMBL932607 | 0.87 | CHEK2 (0.36) | TSHRLMNAMEN1MAPTKMT2A | |
| SCHEMBL12661149 | 0.87 | GPR119 (0.36) | TSHRLMNAMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | TSHR 4599/4885LMNA 3337/4885MEN1 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.